3篇
您的检索式：作者名="Emmanuelle Samalin"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neoadjuvant therapy for gastroesophageal adenocarcinoma显示文摘Gastric and esophageal adenocarcinomas are one of the main causes of cancer-related death worldwide. While the incidence of gastric adenocarcinoma is decreasing, the incidence of gastroesophageal junction adenocarcinoma is rising rapidly in Western countries. Considering that surgical resection is currently the major curative treatment, and that the 5-year survival rate highly depends on the p TNM stage at diagnosis, gastroesophageal adenocarcinoma management is very challenging for oncologists. Several treatment strategies are being evaluated, and among them systemic chemotherapy, to decrease recurrences and improve overall survival. The MAGIC and FNCLCCFFCD trials showed a survival benefit of perioperative chemotherapy in patients with operable gastric and lower esophageal cancer, and these results had an impact on the European clinical practice. New strategies, including induction chemotherapy followed by preoperative chemoradiotherapy, targeted therapies in combination with perioperative chemotherapy and the new cytotoxic regimens, are currently assessed to improve current standards and help developing patienttailored therapeutic interventions. | Emmanuelle Samalin Marc Ychou | 2016 | World Journal of Clinical Oncology2016，7，3： | 4 |
| 2 | The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer显示文摘 | Thierry Conroy Céline Gavoille Emmanuelle Samalin Marc Ychou Michel Ducreux | 2013 | Current Oncology Reports2013，，2： | 1 |
| 3 | Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer显示文摘AIM:To investigate second-line chemotherapy in gemcitabine-pretreated patients with advanced or metastatic pancreatic cancer [(frequency,response,outcome,course of carbohydrate antigen 19-9 (CA 19-9)].METHODS:This retrospective study included all patients with advanced or metastatic pancreatic cancer (adenocarcinoma or carcinoma) treated with secondline chemotherapy in our center between 2000 and 2008.All patients received first-line chemotherapy with gemcitabine,and prior surgery or radiotherapy was permitted.We analyzed each chemotherapy protocol for second-line treatment,the number of cycles and the type of combination used.The primary endpoint was overall survival.Secondary endpoints included progression-free survival,response rate,grade 3-4 toxicity,dosage modifications and CA 19-9 course.RESULTS:A total of eighty patients (38%) underwenta second-line therapy among 206 patients who had initially received first-line treatment with a gemcitabine-based regimen.Median number of cycles was 4 (range:1-12) and the median duration of treatment was 2.6 mo (range:0.3-7.4).The overall disease control rate was 40.0%.The median overall survival and progression-free survival from the start of second-line therapy were 5.8 (95% CI:4.1-6.6) and 3.4 mo (95% CI:2.4-4.2),respectively.Toxicity was generally acceptable.Median overall survival of patients with a CA 19-9 level declining by more than 20% was 10.3 mo (95% CI:4.5-11.6) vs 5.2 mo (95% CI:4.0-6.4) for others (P=0.008).CONCLUSION:A large proportion of patients could benefit from second-line therapy,and CA 19-9 allows efficient treatment monitoring both in first and secondline chemotherapy. | Romain Altwegg Marc Ychou Vanessa Guillaumon Simon Thezenas Pierre Senesse Nicolas Flori Thibault Mazard Ludovic Caillo Stéphanie Faure Emmanuelle Samalin Eric Assenat | 2012 | World Journal of Gastroenterology2012，18，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员